Business Context and Reporting Period
This Form 8-K filing by MacroGenics, Inc. reports a corporate governance event dated February 25, 2016, with the effective date of the change being March 1, 2016. The filing details the promotion of an existing executive officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation adjustments.
Material Changes
The primary material change is the promotion of Jon Wigginton, M.D., from Senior Vice President, Clinical Development, to Senior Vice President, Clinical Development and Chief Medical Officer. Associated compensation changes include:
- Base Salary: Set at $430,000 annually.
- Performance Bonus: Target set at 40% of the base salary.
- Equity Grant: Award of 30,000 Restricted Share Units (RSUs).
Guidance, Outlook, and Risks
The filing contains no financial guidance, market outlook, or discussion of general business risks. Regarding contingencies, the RSU grant includes an acceleration provision: in the event of termination by the Company other than for cause, all unvested RSUs shall immediately vest. The RSUs otherwise vest fully after two years subject to continued employment.
Investor Verification Points
- Confirm the effective date of the new Chief Medical Officer role (March 1, 2016).
- Verify the total potential annual cash compensation ($430,000 base + 40% bonus target).
- Review the vesting schedule and acceleration terms for the 30,000 RSU grant.
- Check for any related party transactions, which the filing explicitly states do not exist for this individual.